CORAL GABLES, FL / ACCESSWIRE / October 10, 2017 / Here are two biotech stocks to watch after both companies released news on Tuesday pre-market:
GT Biopharma, Inc. (GTBP) has seen an increase in trading activity since the beginning of October. On Tuesday morning (10/10/17), GTBP announced the completion of the first four patients in their FDA approved phase 2 clinical trials for its cancer therapy, OXS-1550.
Dr. Kathleen Clarence-Smith, CEO of GT Biopharma, Inc., stated, "The product performed well in Phase 1 studies of blood cancers, enrollment in the Phase II study is advancing rapidly, and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors."
"Nicox's NO-donating research platform has been validated in both pre-clinical and human studies for the reduction of IOP," stated Nancy Lurker, President & CEO of pSivida. "Combining this novel approach to IOP lowering with our bioerodible, sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma."
BIOTECHSTOCKS.com (BTS) is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by GT Biopharma Inc. for a period beginning August 1, 2017 and ending Oct. 1, 2017, now extended to November 1, 2017, to publicly disseminate information about GTBP. Full Disclaimer Here.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.
BTS, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.